Tuberculosis infections and tumor necrosis factor alpha antagonists

Am J Ther. 2013 Jan;20(1):73-8. doi: 10.1097/MJT.0b013e31820b8846.

Abstract

The treatment of rheumatologic diseases with tumor necrosis factor-alpha antagonists has become common practice. Studies have demonstrated an increased risk of active tuberculosis with use of tumor necrosis factor-alpha antagonists. We aim to better define the risk of tuberculosis infection associated with tumor necrosis factor-alpha antagonists and to review the literature on the treatment of latent tuberculosis.

Publication types

  • Review

MeSH terms

  • Adalimumab
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Antirheumatic Agents / adverse effects*
  • Antitubercular Agents / therapeutic use
  • Etanercept
  • Europe / epidemiology
  • Humans
  • Immunoglobulin G / adverse effects*
  • Immunosuppressive Agents / adverse effects*
  • Infliximab
  • Latent Tuberculosis / drug therapy
  • Mass Screening
  • Quebec / epidemiology
  • Receptors, Tumor Necrosis Factor
  • Tuberculosis / chemically induced*
  • Tuberculosis / diagnosis
  • Tuberculosis / epidemiology
  • Tuberculosis / prevention & control
  • United States / epidemiology

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Antitubercular Agents
  • Immunoglobulin G
  • Immunosuppressive Agents
  • Receptors, Tumor Necrosis Factor
  • Infliximab
  • Adalimumab
  • Etanercept